Emergent BioSolutions Inc. (EBS)
Lazard Capital Markets Healthcare Conference 2011
November 16, 2012 10:00 AM ET
Don Elsey – Senior Vice President Finance & Administration and Chief Financial Officer
Hi, good morning, and today we are here to hear more about Emergent BioSolutions, and speaking to you is Don Elsey.
Good morning. Thank you for joining us this morning. I am told I have 25 minutes, and it is a hard stop. So that should not be a problem. So forward-looking statements, our normal disclaimer. We may say things here that the actual results differ from, and if you haven’t heard that 500 times, you haven’t been in any of these.
So let me tell you about EBS for those of you who don’t know us, EBS at a glance. So we have got one licensed product, which is the only FDA approved anthrax vaccine, and that we sell on a regular basis to the US government for stockpiling purposes. We will get into that more later on. We are organized into two divisions, biodefense and biosciences, focused on three disease areas, infectious diseases, oncology and autoimmune. We will get into the components of each of those as we go through the presentation, and we have got eight clinical stage product candidates currently, and a nine-year track record of profitability, and hopefully making that a 10-year track record of profitability.
So let us go and take a look at the eight clinical candidates, and we will come back to BioThrax, our licensed anthrax vaccine in a moment. So starting at the top and what you see here is mixture of bio defense and bioscience candidates. So Anthrivig, which is a polyclonal anthrax therapeutic, basically in a phase 3. This is of course all animal studies. This is underwritten by the government as it currently stands, whether it gets to a procurement stage, we will have to see.